Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:43:07.633Z.
Consensus retrieved: 2026-10-06T15:49:32.629Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:43:07.633Z.
Quote observation: 2026-10-06T19:40:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 24a0b8a5defa6360a8df5348432e42fec2fdf5a1d44ff9a0d63a76d612d48360
Forward PE Ratio (N/A) = Dated Quote Price ($13.12) / Consensus Forward EPS ($-2.89)
FORWARD PE RATIO
N/A
Replimune Group, Inc.
Market Cap
$1.10B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Replimune Group, Inc. (REPL) | $1.10B | N/A |
| OPKO Health, Inc. (OPK)vs › | $1.10B | N/A |
| Tandem Diabetes Care, Inc. (TNDM)vs › | $1.10B | N/A |
| STAAR Surgical Company (STAA)vs › | $1.10B | 75.89 |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.12B | N/A |
| First Tracks Biotherapeutics Inc (TRAX)vs › | $1.09B | N/A |
| IRadimed Corporation (IRMD)vs › | $1.08B | 40.03 |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.13B | 8.61 |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.07B | N/A |
| Harrow Health, Inc. (HROW)vs › | $1.13B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2027-03-31
At the dated quote price of $13.12, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-03-31 | $-2.89 | $-3.29 – $-2.54 | 4 | n/m |
| 2028-03-31 | $-1.91 | $-2.32 – $-1.70 | 4 | n/m |
| 2029-03-31 | $-0.71 | $-1.73 – $-0.18 | 4 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
